Loading...
Cipla Limited — Lenalidomide Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Lenalidomide · $2.1M export value · DGFT Verified
Cipla Limited is the #4 Indian exporter of Lenalidomide with $2.1M in export value and 42 verified shipments. Cipla Limited holds a 1.5% market share in Lenalidomide exports across 6 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| COLOMBIA | $400.0K | 8 | 31.2% |
| AUSTRALIA | $398.3K | 10 | 31.1% |
| SOUTH AFRICA | $250.0K | 5 | 19.5% |
| UNITED STATES | $200.0K | 4 | 15.6% |
| PAKISTAN | $28.4K | 6 | 2.2% |
| BRAZIL | $5.1K | 9 | 0.4% |
Cipla Limited exports Lenalidomide to 6 countries. The largest destination is COLOMBIA accounting for 31.2% of Cipla Limited's Lenalidomide shipments, followed by AUSTRALIA (31.1%) and SOUTH AFRICA (19.5%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA AUSTRALIA PTY LTD | AUSTRALIA | $398.3K | 10 |
| CIPLA USA INC UPS SUPPLY CHAIN SOL | UNITED STATES | $200.0K | 4 |
| CIPLA COLOMBIA SAS Y O DEPOSITO UPS | COLOMBIA | $150.0K | 3 |
| MEDPRO PHARMACEUTICA (PTY) LIMITED | SOUTH AFRICA | $150.0K | 3 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UPS | COLOMBIA | $100.0K | 2 |
| MEDPRO PHARMACEUTICA PTY LIMITED |
India exported $30.4M worth of Lenalidomide through 2,724 shipments from 237 suppliers to 122 countries, serving 557 buyers globally. Cipla Limited contributes $2.1M to this total, accounting for 1.5% of India's Lenalidomide exports. Cipla Limited ships Lenalidomide to 6 countries through 12 buyers.
Cipla Limited's average Lenalidomide shipment value is $50.0K per consignment, based on 42 shipments totaling $2.1M. The largest destination is COLOMBIA (31.2% of Cipla Limited's Lenalidomide exports).
Cipla Limited ranks #4 among 237 Indian Lenalidomide exporters with a 1.5% market share. The top 3 exporters are EUGIA PHARMA SPECIALITIES LIMITED ($9.4M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($8.3M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($7.2M). Cipla Limited processed 42 shipments to 6 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CIPLA LENALIDOMIDE 10MG CAPSULES (LENALI | $116.7K | 3 |
| CIPLA LENALIDOMIDE 15MG CAPSULES (LENALI | $114.0K | 3 |
| CIPLA LENALIDOMIDE 5MG CAPSULES (LENALID | $96.5K | 2 |
| CIPLA LENALIDOMIDE 25MG CAPSULES (LENALI | $71.1K | 2 |
| LENALIDOMIDE CIPLA 25 CAPSULES LENALIDO | $50.0K | 1 |
| LENOSIDE 15MG CAPSULES LENALIDOMIDE 15 | $50.0K | 1 |
| LENOSIDE 10MG CAPSULES LENALIDOMIDE 10 | $50.0K | 1 |
| LENOSIDE 10 MG CAPSULES LENALIDOMIDE 10MG CAPSULES DOCUMENT QTY 3000 PACK 3X7=63000 NOS | $50.0K | 1 |
| LENALIDOMIDE CIPLA 25 CAPSULES (LENALIDOMIDE) [PAC SIZE:3X7X2134 PAC=44814 NOS] |
What Cipla Limited must comply with to export Lenalidomide to its top destination countries
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $8.3M | 281 | 16 | $29.4K |
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $7.2M | 144 | 6 | $50.0K |
| 4 | CIPLA LIMITED ★ | $2.1M | 42 | 6 | $50.0K |
| 6 | HETERO LABS LIMITED | $1.1M | 23 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 740 | 27.2% |
| SAHAR AIR | 688 | 25.3% |
| DELHI AIR CARGO ACC (INDEL4) | 187 | 6.9% |
| Bombay Air | 180 | 6.6% |
| DELHI AIR | 140 | 5.1% |
| Bombay Air Cargo | 88 | 3.2% |
| HYDERABAD ACC (INHYD4) | 78 | 2.9% |
| HYDERABAD AIR | 68 | 2.5% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Lenalidomide, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Lenalidomide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Lenalidomide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
| SOUTH AFRICA |
| $50.0K |
| 1 |
| CIPLA COLOMBIA SAS | COLOMBIA | $50.0K | 1 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $50.0K | 1 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UP | COLOMBIA | $50.0K | 1 |
| CIPLA COLOMBIA SAS Y O DEPOSITO UP | COLOMBIA | $50.0K | 1 |
Cipla Limited supplies Lenalidomide to 12 buyers globally. The largest buyer is CIPLA AUSTRALIA PTY LTD (AUSTRALIA), followed by CIPLA USA INC UPS SUPPLY CHAIN SOL (UNITED STATES) and CIPLA COLOMBIA SAS Y O DEPOSITO UPS (COLOMBIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| $50.0K |
| 1 |
| LENALIDOMIDE CIPLA 25 CAPSULES (LENALIDOMIDE) [PAC SIZE:3X7X2144 PAC=45024 NOS] | $50.0K | 1 |
Cipla Limited exports 31 distinct Lenalidomide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CIPLA LENALIDOMIDE 10MG CAPSULES (LENALI with 3 shipments worth $116.7K.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 8 |
| $50.0K |
| 7 | NATCO PHARMA LIMITED | $1.1M | 31 | 6 | $35.6K |
Cipla Limited ranks #4 among 237 Indian Lenalidomide exporters. Average shipment value of $50.0K compared to the market average of $128.1K. The closest competitors by value are RELIANCE LIFE SCIENCES PRIVATE LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 122+ countries, 557+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Lenalidomide. For current shipment-level data, contact TransData Nexus.